You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

TENORETIC 100 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tenoretic 100 patents expire, and what generic alternatives are available?

Tenoretic 100 is a drug marketed by Twi Pharms and is included in one NDA.

The generic ingredient in TENORETIC 100 is atenolol; chlorthalidone. There are thirty-four drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the atenolol; chlorthalidone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tenoretic 100

A generic version of TENORETIC 100 was approved as atenolol; chlorthalidone by TWI PHARMS on May 31st, 1990.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TENORETIC 100?
  • What are the global sales for TENORETIC 100?
  • What is Average Wholesale Price for TENORETIC 100?
Summary for TENORETIC 100
Drug patent expirations by year for TENORETIC 100
Pharmacology for TENORETIC 100

US Patents and Regulatory Information for TENORETIC 100

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Twi Pharms TENORETIC 100 atenolol; chlorthalidone TABLET;ORAL 018760-001 Jun 8, 1984 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TENORETIC 100

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Twi Pharms TENORETIC 100 atenolol; chlorthalidone TABLET;ORAL 018760-001 Jun 8, 1984 3,663,607 ⤷  Subscribe
Twi Pharms TENORETIC 100 atenolol; chlorthalidone TABLET;ORAL 018760-001 Jun 8, 1984 3,934,032 ⤷  Subscribe
Twi Pharms TENORETIC 100 atenolol; chlorthalidone TABLET;ORAL 018760-001 Jun 8, 1984 3,836,671 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TENORETIC 100

See the table below for patents covering TENORETIC 100 around the world.

Country Patent Number Title Estimated Expiration
Switzerland 553747 VERFAHREN ZUR HERSTELLUNG VON ALKANOLAMINDERIVATEN. ⤷  Subscribe
Yugoslavia 193575 ⤷  Subscribe
U.S.S.R. 452091 ⤷  Subscribe
Yugoslavia 193375 ⤷  Subscribe
Switzerland 547257 VERFAHREN ZUR HERSTELLUNG VON ALKANOLAMINDERIVATEN. ⤷  Subscribe
Austria 305245 ⤷  Subscribe
Czechoslovakia 153063 ZPUSOB VYROBY FENOXYPROPANOLAMINU ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

TENORETIC 100 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Tenoretic 100

Introduction to Tenoretic 100

Tenoretic 100 is a combination medication consisting of atenolol, a beta-blocker, and chlorthalidone, a thiazide diuretic. This drug is primarily used to treat hypertension (high blood pressure), reducing the risk of stroke and heart attack[5].

Global Market Overview

The global market for atenolol, a key component of Tenoretic 100, is projected to experience significant growth. As of 2023, the atenolol market was valued at USD 11.59 billion and is expected to reach USD 22.97 billion by 2036, growing at a CAGR of approximately 5.4% during the forecast period of 2024-2036[1].

Key Growth Drivers

Several factors are driving the growth of the atenolol market, which in turn affects the demand for Tenoretic 100:

Increasing Prevalence of Hypertension

The global prevalence of hypertension is rising, with an estimated 1.28 billion people aged 30-79 years suffering from the condition. This increase is particularly pronounced in low- and middle-income countries, where two-thirds of these individuals reside[1].

Aging Population

The global population of people aged 60 and above is projected to increase from 1 billion in 2020 to 1.4 billion by 2030 and further to 2.1 billion by 2050. This demographic shift is expected to fuel the demand for antihypertensive drugs, including Tenoretic 100[1].

Lifestyle Factors

Poor lifestyle and dietary habits are contributing to the rising incidence of hypertension and other cardiovascular diseases, thereby increasing the demand for medications like Tenoretic 100[1].

Market Segmentation

The global atenolol market is segmented based on application and distribution channels.

Application Segmentation

  • The hypertension segment is expected to dominate the market, accounting for approximately 55% of the market share by 2036. This is due to the increasing prevalence of hypertension and the growing demand for antihypertensive drugs[1].

Distribution Channel Segmentation

  • Hospital pharmacies are expected to hold a significant share of around 49% by 2036, driven by the increasing patient pool seeking treatment for hypertension and other cardiovascular diseases. Online pharmacies are also projected to witness impressive growth due to rising internet penetration and user awareness[1].

Regional Market Dynamics

The market for atenolol and consequently Tenoretic 100 varies across different regions:

Asia Pacific

  • This region is expected to be the second largest market, with a share of about 28% by 2036. The growth is driven by the rising burden of hypertension, increasing population, and changing lifestyles in the region[1].

Europe

  • The European market is projected to hold a noteworthy share of about 17% by 2036. This is attributed to the high incidence of cardiovascular diseases in the region and the availability of efficient and inexpensive healthcare facilities[1].

Financial Trajectory

The financial performance of Tenoretic 100 is closely tied to the overall atenolol market.

Sales and Revenue

  • In 2018, AstraZeneca's established hypertension medicines, including Tenoretic, generated annual sales of $132 million. Although AstraZeneca has since divested the rights to these medicines to Atnahs Pharma, the demand for these drugs remains strong[4].

Generic Competition

  • The market for Tenoretic 100 also includes generic versions. For instance, Unichem Laboratories Limited obtained ANDA authorization from the USFDA for its generic version of Tenoretic, which is expected to compete in the market[1].

Challenges and Opportunities

While the market for Tenoretic 100 is growing, there are several challenges and opportunities to consider:

Challenges

  • The presence of generic competitors can reduce the market share of branded versions of Tenoretic 100.
  • Regulatory changes and the need for continuous clinical trials to maintain market approval can be challenging.

Opportunities

  • Increasing awareness about hypertension and the importance of antihypertensive medications presents a significant opportunity for growth.
  • Expanding into new markets, particularly in regions with high prevalence rates of hypertension, can further boost sales.

Key Takeaways

  • The global atenolol market, and by extension the market for Tenoretic 100, is expected to grow significantly due to the increasing prevalence of hypertension and an aging population.
  • The hypertension segment will dominate the market, with hospital pharmacies being the primary distribution channel.
  • Regional markets, especially in the Asia Pacific and Europe, will play crucial roles in the growth trajectory.
  • Generic competition and regulatory dynamics will influence the financial performance of Tenoretic 100.

FAQs

1. What is Tenoretic 100 used for?

Tenoretic 100 is a combination medication used to treat hypertension (high blood pressure), reducing the risk of stroke and heart attack[5].

2. What are the key components of Tenoretic 100?

Tenoretic 100 consists of atenolol, a beta-blocker, and chlorthalidone, a thiazide diuretic[5].

3. What is the projected market size for atenolol by 2036?

The atenolol market is expected to reach USD 22.97 billion by 2036, growing at a CAGR of approximately 5.4% during the forecast period[1].

4. Which segment is expected to dominate the atenolol market?

The hypertension segment is expected to dominate the market, accounting for approximately 55% of the market share by 2036[1].

5. Who are the major players in the atenolol market?

Major players include Atnahs Pharma, which acquired the rights to established hypertension medicines from AstraZeneca, and generic manufacturers like Unichem Laboratories Limited[1][4].

Cited Sources:

  1. Research Nester - Atenolol Market Size & Share, Growth Forecasts 2024-2036
  2. ICOFESA S.A - (Not relevant to the topic)
  3. Futura Medical - Preliminary Results and R&D Summary - Futura Medical
  4. AstraZeneca - AstraZeneca divests rights to established hypertension medicines
  5. Drugs.com - Tenoretic 100 Uses, Side Effects & Warnings - Drugs.com

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.